Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

First-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) can improve efficacy of metastatic colorectal cancer (MCRC), KRAS wild-type and mutant. Prognostic relevance of KRAS genotype was evaluated in patients unfit for FIr-B/FOx, treated with conventional medical treatments. Consecutive MCRC pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2014
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063538/
https://ncbi.nlm.nih.gov/pubmed/24715238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2014.2369
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars